GlassScriptPhysician profile
Gregory G Hamrick
NPI 1063476679
$4,057.17
in general payments reported to CMS, 2019-2025
33 companies · $564 in 2025
The $564 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,189 · 2022: $905 · 2023: $664 · 2024: $735 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,316.78 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $355.70 | 2022-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $348.48 | 2021-2024 | Xarelto |
| Amgen INC. | $308.58 | 2021-2024 | Repatha |
| Abbott Laboratories | $262.78 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $226.28 | 2021-2024 | |
| Esperion Therapeutics, INC. | $188.68 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $139.94 | 2021-2025 | |
| Novo Nordisk INC | $135.01 | 2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $88.48 | 2021-2024 | Farxiga |
| Pfizer INC. | $63.60 | 2021-2025 | |
| Amarin Pharma, INC. | $57.55 | 2021 | |
| Chiesi USA, INC. | $56.48 | 2021-2022 | |
| Indivior INC. | $55.49 | 2025 | Sublocade |
| Kiniksa Pharmaceuticals International, Plc | $44.18 | 2024 | Arcalyst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $40.34 | 2025 | Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.49 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.66 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $30.71 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $28.34 | 2025 | Rexulti |
| United Therapeutics Corporation | $27.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.29 | 2021 | |
| Irhythm Technologies, INC. | $24.06 | 2023 | Zio Xt Patch |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.15 | 2025 | Xifaxan |
| Impulse Dynamics (USA) INC. | $20.48 | 2023 | Optimizer |
| Bard Peripheral Vascular, INC. | $15.64 | 2024 | Venovo |
| Lantheus Medical Imaging, INC. | $15.48 | 2021 | |
| Abbvie INC. | $15.11 | 2025 | |
| Exact Sciences Corporation | $14.81 | 2025 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $14.50 | 2023 | |
| Sumitomo Pharma America, INC. | $13.90 | 2025 | Gemtesa |
| Cvrx, INC. | $13.26 | 2023 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hamrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.